| 研究実績の概要 |
<Research Plan 2> Molecular mechanisms how TGF-β regulates differentiation and maturation of DC subsets: I have found that selective repression of SMAD3 directs conventional DC, whereas its maintenance directs plasmacytoid DC differentiation and clarified the molecular mechanisms. I have presented the results at the American Association for Cancer Research Annual Meeting 2017, Washington DC, USA, The 5th Annual Meeting of the International Cytokine and Interferon Society, Kanazawa, Japan and the 46th Annual Meeting of The Japanese Society for Immunology, Sendai, Japan. I have been awarded by 2016 Excellent Thesis Award (Outstanding Doctoral Research Award), University of Tsukuba, Japan and the Kishimoto Travel Awards at the 5th Annual Meeting of the International Cytokine and Interferon Society, Kanazawa, Japan in 2017.
<Research Plan 1> The mechanisms how systemic TGF-β antagonists exert dose-dependent divergent effects on tumor immunity: I have found that the treatment with high-dose activin receptor-like kinase5 inhibitor, EW7197 exacerbated the murine B16 melanoma model by rather accelerating the SMAD-mediated TGF-β signaling via blocking the negative feedback loop. I have found that dose-dependent anti-tumor and tumor-promoting effects of TGF-β antagonists are due to the distinct SMAD expression patterns in cell-specific manners.
<Research Plan 3> Optimization of DC-based anti-tumor immunotherapies using TGF-β antagonists: I have optimized the culture condition for adoptive DC therapy for the murine B16 melanoma model.
|
